Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12425622 | 0.92 | HPGD (0.51) | HPGDUSP2CYP2D6CYP2C19MMP1 | |
| SCHEMBL13373681 | 0.78 | PSMB5 (0.51) | HPGDUSP2CYP2D6CYP2C19MMP1 | |
| SCHEMBL23185124 | 0.75 | LMNA (0.38) | HPGDLMNAPSMB5RECQL | |
| SCHEMBL16771519 | 0.75 | CYP2D6 (0.50) | HPGDUSP2CYP2D6CYP2C19MMP1 | |
| SCHEMBL19818495 | 0.74 | CYP2D6 (0.45) | HPGDUSP2CYP2D6CYP2C19MMP1 | |
| SCHEMBL24778821 | 0.74 | HPGD (0.50) | HPGDUSP2CYP2D6CYP2C19MMP1 | |
| SCHEMBL10026067 | 0.73 | ALDH1A1 (0.31) | HPGDRECQL | |
| SCHEMBL13373810 | 0.73 | CYP2D6 (0.52) | HPGDUSP2CYP2D6CYP2C19MMP1 | |
| SCHEMBL10381056 | 0.73 | CYP2D6 (0.52) | HPGDUSP2CYP2D6CYP2C19MMP1 | |
| SCHEMBL9457494 | 0.73 | EGLN1 (0.41) | HPGDUSP2LMNAKDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133348-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133348-A1 | NUCLEAR IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | CA9, CA14, CA13 | HPGD 1189/4885USP2 2625/4885CYP2D6 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.